Editorial: Non-cellular immunotherapies in pediatric malignancies.
作者信息
Alexander Sarah, Harker-Murray Paul, Hayashi Robert J
机构信息
Pediatrics, Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
出版信息
Front Immunol. 2024 Feb 21;15:1379278. doi: 10.3389/fimmu.2024.1379278. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Non-cellular immunotherapies in pediatric malignancies.
Front Immunol. 2024 Feb 21;15:1379278. doi: 10.3389/fimmu.2024.1379278. eCollection 2024.
2
Immunotherapy in pediatric malignancies: current status and future perspectives.
Future Oncol. 2014;10(9):1659-78. doi: 10.2217/fon.14.62.
3
Immunotherapies for pediatric cancer: current landscape and future perspectives.
Cancer Metastasis Rev. 2019 Dec;38(4):573-594. doi: 10.1007/s10555-019-09819-z.
4
Immunotherapy approaches for rare pediatric solid tumors: advances and future directions.
Curr Opin Pediatr. 2023 Feb 1;35(1):63-74. doi: 10.1097/MOP.0000000000001206. Epub 2022 Nov 24.
5
Cancer immunotherapies, their safety and toxicity.
Expert Opin Drug Saf. 2013 Sep;12(5):631-45. doi: 10.1517/14740338.2013.795944. Epub 2013 May 14.
6
[Not Available].
Bull Cancer. 2018 Dec;105 Suppl 1:S68-S79. doi: 10.1016/S0007-4551(18)30392-8.
7
Harnessing immunotherapy for pediatric T-cell malignancies.
Expert Rev Clin Immunol. 2020 Apr;16(4):361-371. doi: 10.1080/1744666X.2020.1732819. Epub 2020 Feb 27.
8
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
Eur J Pediatr. 2017 Sep;176(9):1163-1172. doi: 10.1007/s00431-017-2982-0. Epub 2017 Aug 12.
9
Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology.
Crit Rev Oncog. 2015;20(3-4):315-27. doi: 10.1615/critrevoncog.2015013861.
10
[Role of Immunotherapy in Pediatric Oncology].
Klin Onkol. 2015;28 Suppl 4:4S38-43. doi: 10.14735/amko20154s38.
本文引用的文献
1
Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.
J Res Med Sci. 2023 Sep 29;28:71. doi: 10.4103/jrms.jrms_727_22. eCollection 2023.
2
CAR-T treatment for cancer: prospects and challenges.
Front Oncol. 2023 Dec 5;13:1288383. doi: 10.3389/fonc.2023.1288383. eCollection 2023.
3
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Front Immunol. 2023 Dec 1;14:1291836. doi: 10.3389/fimmu.2023.1291836. eCollection 2023.
4
Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress.
Cancers (Basel). 2023 Aug 17;15(16):4137. doi: 10.3390/cancers15164137.
5
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
Int J Mol Sci. 2023 Jul 25;24(15):11903. doi: 10.3390/ijms241511903.
6
Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study.
Pathol Res Pract. 2023 Sep;249:154732. doi: 10.1016/j.prp.2023.154732. Epub 2023 Aug 1.
7
The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia.
Hematol Oncol Clin North Am. 2023 Dec;37(6):1041-1052. doi: 10.1016/j.hoc.2023.06.003. Epub 2023 Jul 26.
8
New immunotherapeutic approaches for cancer treatment.
Pathol Res Pract. 2023 Aug;248:154632. doi: 10.1016/j.prp.2023.154632. Epub 2023 Jun 19.
9
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.
J Clin Oncol. 2023 Sep 1;41(25):4118-4129. doi: 10.1200/JCO.22.02200. Epub 2023 May 31.
10
CAR immune cells: design principles, resistance and the next generation.
Nature. 2023 Feb;614(7949):635-648. doi: 10.1038/s41586-023-05707-3. Epub 2023 Feb 22.
Zotero 插件